West Pharm Svcs Financials
This page shows West Pharm Svcs (WST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
West Pharm Svcs has an operating margin of 19.0%, meaning the company retains $19 of operating profit per $100 of revenue. This strong profitability earns a score of 95/100, reflecting efficient cost management and pricing power. This is down from 19.7% the prior year.
West Pharm Svcs's revenue declined 100% year-over-year, from $2.9B to $3K. This contraction results in a growth score of 0/100.
West Pharm Svcs carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.02, West Pharm Svcs holds $3.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
West Pharm Svcs converts 15.3% of revenue into free cash flow ($469). This strong cash generation earns a score of 76/100.
West Pharm Svcs's ROE of 15.5% shows moderate profitability relative to equity, earning a score of 62/100. This is down from 18.4% the prior year.
West Pharm Svcs scores 9897345.36, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($18.0B) relative to total liabilities ($1K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
West Pharm Svcs passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, West Pharm Svcs generates $1.53 in operating cash flow ($755 OCF vs $494 net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
West Pharm Svcs earns $38.7 in operating income for every $1 of interest expense ($585 vs $15). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
West Pharm Svcs generated $3K in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs's EBITDA was $725 in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs generated $469 in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs reported $494 in net income in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs earned $6.79 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1.5% from the prior year.
West Pharm Svcs held $791 in cash against $203 in long-term debt as of fiscal year 2025.
West Pharm Svcs paid $0.78 per share in dividends in fiscal year 2025. This represents a decrease of 4.9% from the prior year.
West Pharm Svcs had 72M shares outstanding in fiscal year 2025. This represents a decrease of 0.4% from the prior year.
West Pharm Svcs's gross margin was 35.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.
West Pharm Svcs's operating margin was 19.0% in fiscal year 2025, reflecting core business profitability. This is down 0.7 percentage points from the prior year.
West Pharm Svcs's net profit margin was 16.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.0 percentage points from the prior year.
West Pharm Svcs's ROE was 15.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.8 percentage points from the prior year.
West Pharm Svcs invested $74 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs spent $134 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
West Pharm Svcs invested $286 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
WST Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $804.6M+5.0% | $766.5M+9.8% | $698.0M-6.8% | $748.8M+6.7% | $702.1M+1.0% | $695.4M-5.0% | $732.0M-2.1% | $747.4M |
| Cost of Revenue | $510.3M+3.6% | $492.6M+5.7% | $466.1M-1.9% | $475.2M+0.7% | $472.1M+1.5% | $465.2M+2.5% | $453.8M-1.2% | $459.1M |
| Gross Profit | $294.3M+7.4% | $273.9M+18.1% | $231.9M-15.2% | $273.6M+19.0% | $230.0M-0.1% | $230.2M-17.3% | $278.2M-3.5% | $288.3M |
| R&D Expenses | $17.1M-10.5% | $19.1M+17.2% | $16.3M-11.9% | $18.5M+5.7% | $17.5M-0.6% | $17.6M-4.3% | $18.4M+12.2% | $16.4M |
| SG&A Expenses | $102.7M+7.1% | $95.9M+9.0% | $88.0M+3.2% | $85.3M+2.8% | $83.0M-4.3% | $86.7M-3.7% | $90.0M+1.1% | $89.0M |
| Operating Income | $167.6M+9.0% | $153.7M+43.6% | $107.0M-33.0% | $159.6M+26.5% | $126.2M+2.8% | $122.8M-23.7% | $160.9M-9.2% | $177.3M |
| Interest Expense | $200K+100.0% | $100K-75.0% | $400K-96.8% | $12.4M+726.7% | $1.5M-6.3% | $1.6M+33.3% | $1.2M-58.6% | $2.9M |
| Income Tax | $34.0M+12.6% | $30.2M+25.3% | $24.1M-34.5% | $36.8M+68.0% | $21.9M+33.5% | $16.4M-52.5% | $34.5M+17.3% | $29.4M |
| Net Income | $140.0M+6.2% | $131.8M+46.8% | $89.8M-31.0% | $130.1M+16.9% | $111.3M-3.5% | $115.3M-15.8% | $137.0M-15.1% | $161.3M |
| EPS (Diluted) | $1.92+5.5% | $1.82+48.0% | $1.23-30.9% | $1.78+17.9% | $1.51-2.6% | $1.55-15.3% | $1.83-14.5% | $2.14 |
WST Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.1B+3.9% | $4.0B+9.2% | $3.6B-0.7% | $3.6B+4.4% | $3.5B-3.1% | $3.6B-5.9% | $3.8B+2.0% | $3.8B |
| Current Assets | $1.8B+8.5% | $1.7B+15.3% | $1.5B-5.2% | $1.5B+3.7% | $1.5B-12.4% | $1.7B-12.6% | $1.9B-1.8% | $2.0B |
| Cash & Equivalents | $628.5M+23.3% | $509.7M+26.1% | $404.2M-16.6% | $484.6M+8.6% | $446.2M-25.9% | $601.8M-29.5% | $853.9M-5.0% | $898.6M |
| Inventory | $438.0M+4.0% | $421.1M+8.3% | $388.7M+3.1% | $377.0M-10.1% | $419.2M-2.5% | $429.9M-1.1% | $434.7M+0.7% | $431.8M |
| Accounts Receivable | $625.0M+7.3% | $582.4M+7.1% | $543.6M-1.6% | $552.5M+15.2% | $479.4M-8.5% | $524.0M+2.3% | $512.0M-1.4% | $519.1M |
| Goodwill | $110.6M-0.3% | $110.9M+3.2% | $107.5M+1.4% | $106.0M-1.2% | $107.3M-0.3% | $107.6M-0.8% | $108.5M+1.6% | $106.8M |
| Total Liabilities | $1.1B+3.0% | $1.0B+9.5% | $935.1M-2.7% | $961.1M+5.3% | $912.6M-1.0% | $921.7M-2.8% | $948.5M+7.0% | $886.5M |
| Current Liabilities | $635.4M+5.1% | $604.6M+14.8% | $526.7M-4.3% | $550.4M-13.1% | $633.7M-2.3% | $648.4M-3.5% | $671.8M+25.9% | $533.5M |
| Long-Term Debt | $202.7M0.0% | $202.6M0.0% | $202.6M0.0% | $202.6M+177.9% | $72.9M+0.1% | $72.8M0.0% | $72.8M-52.1% | $152.1M |
| Total Equity | $3.1B+4.2% | $2.9B+9.2% | $2.7B0.0% | $2.7B+4.1% | $2.6B-3.9% | $2.7B-7.0% | $2.9B+0.4% | $2.9B |
| Retained Earnings | $4.3B+3.0% | $4.1B+2.7% | $4.0B+1.9% | $4.0B+6.3% | $3.7B+2.7% | $3.6B+2.9% | $3.5B+3.1% | $3.4B |
WST Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $197.2M+11.3% | $177.1M+36.9% | $129.4M-31.9% | $190.1M+15.2% | $165.0M+39.6% | $118.2M-50.6% | $239.1M+3.9% | $230.1M |
| Capital Expenditures | $63.3M-15.8% | $75.2M+5.5% | $71.3M-32.0% | $104.9M+4.7% | $100.2M+10.6% | $90.6M-16.7% | $108.7M+13.5% | $95.8M |
| Free Cash Flow | $133.9M+31.4% | $101.9M+75.4% | $58.1M-31.8% | $85.2M+31.5% | $64.8M+134.8% | $27.6M-78.8% | $130.4M-2.9% | $134.3M |
| Investing Cash Flow | -$63.3M+15.8% | -$75.2M-5.5% | -$71.3M+32.0% | -$104.8M-3.6% | -$101.2M-11.7% | -$90.6M+16.7% | -$108.8M-13.7% | -$95.7M |
| Financing Cash Flow | -$11.5M+22.8% | -$14.9M+89.9% | -$147.0M-113.4% | -$68.9M+68.4% | -$218.3M+19.4% | -$271.0M-43.0% | -$189.5M-749.8% | -$22.3M |
| Dividends Paid | $15.1M0.0% | $15.1M-0.7% | $15.2M-0.7% | $15.3M+4.8% | $14.6M-0.7% | $14.7M-0.7% | $14.8M+5.7% | $14.0M |
| Share Buybacks | $0-100.0% | $500K-99.6% | $133.5M+145.4% | $54.4M-70.9% | $187.1M-29.9% | $267.0M+50.8% | $177.0M+536.7% | $27.8M |
WST Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.6%+0.9pp | 35.7%+2.5pp | 33.2%-3.3pp | 36.5%+3.8pp | 32.8%-0.3pp | 33.1%-4.9pp | 38.0%-0.6pp | 38.6% |
| Operating Margin | 20.8%+0.8pp | 20.1%+4.7pp | 15.3%-6.0pp | 21.3%+3.3pp | 18.0%+0.3pp | 17.7%-4.3pp | 22.0%-1.7pp | 23.7% |
| Net Margin | 17.4%+0.2pp | 17.2%+4.3pp | 12.9%-4.5pp | 17.4%+1.5pp | 15.8%-0.7pp | 16.6%-2.1pp | 18.7%-2.9pp | 21.6% |
| Return on Equity | 4.6%+0.1pp | 4.5%+1.1pp | 3.4%-1.5pp | 4.9%+0.5pp | 4.3%+0.0pp | 4.3%-0.5pp | 4.8%-0.9pp | 5.6% |
| Return on Assets | 3.4%+0.1pp | 3.3%+0.9pp | 2.5%-1.1pp | 3.6%+0.4pp | 3.2%-0.0pp | 3.2%-0.4pp | 3.6%-0.7pp | 4.3% |
| Current Ratio | 2.87+0.1 | 2.78+0.0 | 2.77-0.0 | 2.79+0.5 | 2.34-0.3 | 2.61-0.3 | 2.88-0.8 | 3.70 |
| Debt-to-Equity | 0.070.0 | 0.070.0 | 0.080.0 | 0.08+0.0 | 0.030.0 | 0.030.0 | 0.03-0.0 | 0.05 |
| FCF Margin | 16.6%+3.4pp | 13.3%+5.0pp | 8.3%-3.1pp | 11.4%+2.2pp | 9.2%+5.3pp | 4.0%-13.8pp | 17.8%-0.2pp | 18.0% |
Similar Companies
Frequently Asked Questions
What is West Pharm Svcs's annual revenue?
West Pharm Svcs (WST) reported $3K in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is West Pharm Svcs's revenue growing?
West Pharm Svcs (WST) revenue declined by 100% year-over-year, from $2.9B to $3K in fiscal year 2025.
Is West Pharm Svcs profitable?
Yes, West Pharm Svcs (WST) reported a net income of $494 in fiscal year 2025, with a net profit margin of 16.1%.
What is West Pharm Svcs's earnings per share (EPS)?
West Pharm Svcs (WST) reported diluted earnings per share of $6.79 for fiscal year 2025. This represents a 1.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is West Pharm Svcs's EBITDA?
West Pharm Svcs (WST) had EBITDA of $725 in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does West Pharm Svcs have?
As of fiscal year 2025, West Pharm Svcs (WST) had $791 in cash and equivalents against $203 in long-term debt.
What is West Pharm Svcs's gross margin?
West Pharm Svcs (WST) had a gross margin of 35.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is West Pharm Svcs's operating margin?
West Pharm Svcs (WST) had an operating margin of 19.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is West Pharm Svcs's net profit margin?
West Pharm Svcs (WST) had a net profit margin of 16.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does West Pharm Svcs pay dividends?
Yes, West Pharm Svcs (WST) paid $0.78 per share in dividends during fiscal year 2025.
What is West Pharm Svcs's return on equity (ROE)?
West Pharm Svcs (WST) has a return on equity of 15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is West Pharm Svcs's free cash flow?
West Pharm Svcs (WST) generated $469 in free cash flow during fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is West Pharm Svcs's operating cash flow?
West Pharm Svcs (WST) generated $755 in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are West Pharm Svcs's total assets?
West Pharm Svcs (WST) had $4K in total assets as of fiscal year 2025, including both current and long-term assets.
What are West Pharm Svcs's capital expenditures?
West Pharm Svcs (WST) invested $286 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does West Pharm Svcs spend on research and development?
West Pharm Svcs (WST) invested $74 in research and development during fiscal year 2025.
Does West Pharm Svcs buy back shares?
Yes, West Pharm Svcs (WST) spent $134 on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
How many shares does West Pharm Svcs have outstanding?
West Pharm Svcs (WST) had 72M shares outstanding as of fiscal year 2025.
What is West Pharm Svcs's current ratio?
West Pharm Svcs (WST) had a current ratio of 3.02 as of fiscal year 2025, which is generally considered healthy.
What is West Pharm Svcs's debt-to-equity ratio?
West Pharm Svcs (WST) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is West Pharm Svcs's return on assets (ROA)?
West Pharm Svcs (WST) had a return on assets of 11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is West Pharm Svcs's Altman Z-Score?
West Pharm Svcs (WST) has an Altman Z-Score of 9897345.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is West Pharm Svcs's Piotroski F-Score?
West Pharm Svcs (WST) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are West Pharm Svcs's earnings high quality?
West Pharm Svcs (WST) has an earnings quality ratio of 1.53x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can West Pharm Svcs cover its interest payments?
West Pharm Svcs (WST) has an interest coverage ratio of 38.7x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is West Pharm Svcs?
West Pharm Svcs (WST) scores 72 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.